Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination
Article first published online: 16 JUL 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 21, Issue 12, pages 1350–1358, December 2012
How to Cite
Velentgas, P., Amato, A. A., Bohn, R. L., Arnold Chan, K., Cochrane, T., Funch, D. P., Dashevsky, I., Duddy, A. L., Gladowski, P., Greenberg, S. A., Kramer, J. M., McMahill-Walraven, C., Nakasato, C., Spettell, C. M., Syat, B. L., Wahl, P. M., Walker, A. M., Zhang, F., Brown, J. S. and Platt, R. (2012), Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidem. Drug Safe., 21: 1350–1358. doi: 10.1002/pds.3321
- Issue published online: 6 DEC 2012
- Article first published online: 16 JUL 2012
- Manuscript Accepted: 13 JUN 2012
- Manuscript Received: 21 APR 2012
- vaccine safety;
- cohort study;
A new meningococcal conjugate vaccine (MCV4) was introduced in 2005. Shortly after, case reports of Guillain–Barré syndrome (GBS), a serious demyelinating disease, began to be reported to the Vaccine Adverse Event Reporting System. In 2006, the Centers for Disease Control and Prevention and the Food and Drug Administration requested the evaluation of GBS risk after MCV4 vaccination. We conducted a study to assess the risk of GBS after MCV4 vaccination using health plan administrative and claims data together with the review of primary medical records of potential cases.
Retrospective cohort study among 12.6 million 11- to 21-year-old members of five US health plans with a total membership of 50 million. Automated enrollment and medical claims data from March 2005 through August 2008 were used to identify the population, the vaccinations administered, and the medical services associated with possible GBS. Medical records were reviewed and adjudicated by a neurologist panel to confirm cases of GBS. The study used distributed data analysis methods that minimized sharing of protected health information.
We confirmed 99 GBS cases during 18,322,800 person-years (5.4/1,000,000 person-years). More than 1.4 million MCV4 vaccinations were observed. No confirmed cases of GBS occurred within 6 weeks after vaccination. The upper 95% CI for the attributable risk of GBS associated with MCV4 is estimated as 1.5 cases per 1,000,000 doses.
Among members of five US health plans, MCV4 vaccination was not associated with increased GBS risk. Copyright © 2012 John Wiley & Sons, Ltd.